FDA approves Roche ’s Lucentis (ranibizumab injection) for diabetic retinopathy, the leading cause of blindness among working age adults in the United States
Roche today announced that the US Food and Drug Administration (FDA) approved Lucentis ® (ranibizumab injection) 0.3 mg for the monthly treatment of withal forms of diabetic retinopathy.
Source: Roche Investor Update - Category: Pharmaceuticals Source Type: news
More News: Blindness | Diabetes | Endocrinology | Food and Drug Administration (FDA) | Lucentis | Opthalmology | Pharmaceuticals | Ranibizumab Injection